In the context of treating APL, ATO induces terminal differentiation both in vitro and in vivo via the proteasomal degradation of the retinoic acid receptor-alpha gene (PML-RARα) fusion protein, which is mainly involved in the pathogenesis of APL [8]. Here, PML is linked to acute promyelocytic leukemia.